December 11, 2023 08:19 AM ESTUpdated 08:33 AM
Pharma
FDA+

ICER un­veils lat­est re­port on 'un­sup­port­ed' drug price in­creas­es

Zachary Brennan

Senior Editor

The drug pric­ing watch­dog known as the In­sti­tute for for Clin­i­cal and Eco­nom­ic Re­view on Mon­day un­veiled its an­nu­al re­port on what it says are …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times